Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00066703 · ClinicalTrials.gov registry record · Phase 3
Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
A Phase 3 study of Breast Cancer, sponsored by ETOP IBCSG Partners Foundation.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,672
- Enrollment target
- 20
- Study locations
NCT00066703 is a Phase 3 study of Breast Cancer that has completed, run by ETOP IBCSG Partners Foundation. The registered enrollment target is 2,672 participants, roughly in line with the 2,801-participant average among 1,224 other Breast Cancer trials with a reported enrollment target. The trial reports 20 study locations across 7 states.
The verdict
NCT00066703, a Phase 3 study of Breast Cancer, has completed, sponsored by ETOP IBCSG Partners Foundation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,672 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using triptorelin, exemestane, and tamoxifen may fight breast cancer by blocking the use of estrogen. It is not yet known whether giving triptorelin together with exemestane is more effective than triptorelin and tamoxifen in treating hormone-responsive breast cancer. PURPOSE: This randomized phase III trial is studying triptorelin and exemestane to see how well they work compared to triptorelin and tamoxifen in treating premenopausal women with hormone-responsive breast cancer.
Conditions Studied
Interventions
- DRUG exemestane
- DRUG tamoxifen
- DRUG triptorelin
Study Locations (20)
California
- Roy and Patricia Disney Family Cancer Center at Providence Saint Joseph Medical Center - Burbank
- Rebecca and John Moores UCSD Cancer Center - La Jolla
- Providence Holy Cross Cancer Center - Mission Hills
- Desert Regional Medical Center Comprehensive Cancer Center - Palm Springs
- Sutter Cancer Center at Roseville Medical Center - Roseville
- Sutter Cancer Center - Sacramento
- Mercy General Hospital - Sacramento
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
- Ruby L. Golleher Cancer Program at Presbyterian Intercommunity Hospital - Whittier
Colorado
- University of Colorado Cancer Center at UC Health Sciences Center - Aurora
- Shaw Regional Cancer Center - Edwards
- Poudre Valley Hospital - Fort Collins
- Front Range Cancer Specialists - Fort Collins
District of Columbia
- Sibley Memorial Hospital - Washington D.C.
- Walter Reed Army Medical Center - Washington D.C.
Idaho
- Mountain States Tumor Institute at St. Luke's Regional Medical Center - Boise
- Kootenai Cancer Center - Coeur d'Alene - Coeur d'Alene
Connecticut
- Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center - Farmington
Florida
- Mayo Clinic - Jacksonville - Jacksonville
Georgia
- Northeast Georgia Medical Center - Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,672 participants |
| Start Date | 2003-11-03 |
| Est. Completion | 2024-10-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00066703
The ClinicalTrials.gov registry entry for NCT00066703 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,672 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 2,801-participant average among 1,224 other Breast Cancer trials with a reported enrollment target. The listed sponsor is ETOP IBCSG Partners Foundation, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which exemestane is the first listed.
NCT00066703 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Colorado, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT00066703 about?
NCT00066703 is a clinical study titled "Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer". RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using triptorelin, exemestane, and tamoxifen may fight breast cancer by blocking the use of estrogen. It is not yet known whether giving triptorelin together with exemestane is more effective than triptorelin and ta...
What is the current status of trial NCT00066703?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,672 participants. The study started on 2003-11-03. Estimated completion is 2024-10-23.
What conditions does trial NCT00066703 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT00066703?
The interventions under investigation include: exemestane (DRUG), tamoxifen (DRUG), triptorelin (DRUG).
Who is sponsoring clinical trial NCT00066703?
This trial is sponsored by ETOP IBCSG Partners Foundation, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00066703 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
RECRUITING · Phase 3
-
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
RECRUITING · Phase 3
-
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
RECRUITING · Phase 3
-
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
RECRUITING · Phase 3
-
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.